Lotte Steuten - OHE - Page 2

We found for

Eye-Disease Gene-Therapies blog

Insight
February 2023

Cost-effectiveness Analysis of Gene Therapies for Inherited Eye Disease: Are Current Discounting Approaches Too Short-sighted?

The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe

Read more

© Eplisterra - stock.adobe.com

Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies

Insight
January 2023

Combination Therapies: A Step Forward to the Value Attribution Problem

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

Read more

© photoguns

Blog 4

Insight
October 2022

The Economics of Antibiotics – Part 4: What Does the Antibiotics Market of the Future Look Like?

Insight
October 2022

The Economics of Antibiotics – Part 3: Creating a Healthy Global Market for New Antibiotics

Insight
October 2022

The Economics of Antibiotics – Part 2: Value Assessment within the NICE-NHS AMR Pilot

Insight
October 2022

The Economics of Antibiotics – Part 1: Why NICE and NHS England are Testing an Innovative HTA and Payment Model to Tackle Antimicrobial Resistance

Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies

Read more

© WellcomeCollection

Insight
March 2021

International Women’s Day: Why We #Choosetochallenge

Making Outcome-Based Payment a Reality in the NHS. Phase Two: Practical Considerations

Read more

© Rawpixel.com

After the Transplant: Potential Benefits for the NHS and UK Kidney Transplant Patients

Read more

The Value of Vaccines in Maintaining Health System Capacity in England

Read more

Working Towards a Sustainable, Healthy Market for Vaccines: a Comprehensive Framework to Support Policy Dialogue and Decision-Making

Read more

Realising The Broader Value of Vaccines in the UK: Ready for Prime Time?

Read more

Why we need a new Outcomes-based Value Attribution Framework for Combination Regimens in Oncology

Read more

01
02
03